Multicenter, open label, six arms factorial phase III randomized study comparing anastrozole, letrozole and exemestane used upfront (for 5 years) arms A, B, C or sequentially (for 3 years after 2 years of tamoxifen) arms D, E, F, as adjuvant treatment of postmenopausal patients with endocrine-responsive breast cancer.
A phase III study comparing anastrozole, letrozole and exemastane, upfront (for 5 year) or sequentially (for 3 years after 2 years of tamoxifen), as adjuvant treatment of postmenopausal patients with endocrine-responsive breast cancer / DI RENZO, GIANFRANCO MARIA LUIGI. - (2007).
A phase III study comparing anastrozole, letrozole and exemastane, upfront (for 5 year) or sequentially (for 3 years after 2 years of tamoxifen), as adjuvant treatment of postmenopausal patients with endocrine-responsive breast cancer
DI RENZO, GIANFRANCO MARIA LUIGI
2007
Abstract
Multicenter, open label, six arms factorial phase III randomized study comparing anastrozole, letrozole and exemestane used upfront (for 5 years) arms A, B, C or sequentially (for 3 years after 2 years of tamoxifen) arms D, E, F, as adjuvant treatment of postmenopausal patients with endocrine-responsive breast cancer.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
